Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Overlap of post-CAR T HLH toxicity definitions and their prognostic significance in children and young adults with B-acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2025-4501

Published: 2025

Journal Articles

Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults

Blood (2025) 146 (Supplement 1): 7638.

https://doi.org/10.1182/blood-2025-7638

Published: 2025

Journal Articles

Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study

Abigale Berry, Caitlin Elgarten, Yimei Li, Hongyan Liu, Katherine Lind, Daniel Zheng, Gabriella Nguyen, Vanessa Fabrizio, Maria Ortega, Jeremy Rubinstein, Troy Quigg, Anurekha Hall, Deepa Bhojwani, Nirali Shah, Shannon Maude, Sara Zarnegar-Lumley, Allison Weisnicht, Keri Toner, Molly Thornock, Stephanie Thomas, Nicholas Tastet, Heather Symons, Jamie Shoag, Amanda Saraf, April Rahrig, Mahvish Rahim, Alexandra Prosser-Dombrowski, Thomas Pfeiffer, Hiren Patel, Megan Murphy, Lindsey Murphy, Amy Moskop, Giselle Moore-Higgs, Jordan Milner, Kevin McNerney, Cathy Lee-Miller, Mira Kohorst, Hannah Kinoshita, Elizabeth Krieger, Smitha Vasanna, Alex Hoover, Ashley Hinson, Miza Salim Hammoud, Darcy Hamill, Erin Goode, Kelly Faulk, Alejandra Escobar Vasco, Lyannette Elo, Anna Elias, Elizabeth Eom, Jennifer Drinkwine, J. Gregory Dolan, Laurie Davis, Roland Chu, Eliza Briscoe, Deepika Bhatla, Jill Beck, Abdulla Al-Mulla, Ibrahim Ahmed, Lena Winestone, Regina Myers

Blood (2025) 146 (Supplement 1): 4525.

https://doi.org/10.1182/blood-2025-4525

Published: 2025

Journal Articles

Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy

Regina Myers, Yimei Li, Hongyan Liu, Alex Hoover, Laura Shinehouse, Ashley Hinson, Mira Kohorst, Anna Elias, Ella Keenan, Hannah Acres, Ibrahim Ahmed, Abdulla Al-Mulla, Laura Arthur, Jill Beck, Abigale Berry, Deepika Bhatla, Eliza Briscoe, Grace Chang, Roland Chu, Laurie Davis, J. Gregory Dolan, Lyannette Elo, Elizabeth Eom, Alejandra Escobar Vasco, Vanessa Fabrizio, Kelly Faulk, Victor Galan-Gomez, Erin Goode, Stephan Grupp, Anurekha Hall, Darcy Hamill, Smitha Vasanna, Hannah Kinoshita, Elizabeth Krieger, Cathy Lee-Miller, Katherine Lind, Jordan Milner, Giselle Moore-Higgs, Amy Moskop, Lindsey Murphy, Megan Murphy, Gabriella Nguyen, Maria Ortega, Hiren Patel, Antonio Perez, Thomas Pfeiffer, Alexandra Prosser-Dombrowski, Mahvish Rahim, April Rahrig, Shanti Ramachandran, Miza Salim Hammoud, Amanda Saraf, Jamie Shoag, Heather Symons, Nicholas Tastet, Stephanie Thomas, Molly Thornock, Keri Toner, Allison Weisnicht, Sara Zarnegar-Lumley, Nirali Shah, Shannon Maude, Jeremy Rubinstein, Troy Quigg, Deepa Bhojwani, Caitlin Elgarten

Blood (2025) 146 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2025-3339

Published: 2025

Journal Articles

Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study

Katherine Lind, Abigale Berry, Yimei Li, Hongyan Liu, Jeremy Rubinstein, Gabriella Nguyen, Vanessa Fabrizio, Anurekha Hall, Deepa Bhojwani, Troy Quigg, Shannon Maude, Nirali Shah, Maria Ortega, Abdulla Al-Mulla, Ibrahim Ahmed, Jill Beck, Deepika Bhatla, Eliza Briscoe, Roland Chu, Laurie Davis, J. Gregory Dolan, Jennifer Drinkwine, Anna Elias, Lyannette Elo, Elizabeth Eom, Kelly Faulk, Erin Goode, Darcy Hamill, Miza Salim Hammoud, Ashley Hinson, Alex Hoover, Hannah Kinoshita, Mira Kohorst, Elizabeth Krieger, Cathy Lee-Miller, Kevin McNerney, Jordan Milner, Amy Moskop, Giselle Moore-Higgs, Lindsey Murphy, Megan Murphy, Hiren Patel, Thomas Pfeiffer, Alexandra Prosser-Dombrowski, Mahvish Rahim, April Rahrig, Amanda Saraf, Jamie Shoag, Heather Symons, Nicholas Tastet, Stephanie Thomas, Molly Thornock, Keri Toner, Smitha Vasanna, Alejandra Escobar Vasco, Allison Weisnicht, Sara Zarnegar-Lumley, Lena Winestone, Regina Myers, Caitlin Elgarten

Blood (2025) 146 (Supplement 1): 6292.

https://doi.org/10.1182/blood-2025-6292

Published: 2025

Journal Articles

Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Blood (2024) 144 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2024-211231

Published: 2024

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Richard T. Maziarz, Amy Moskop, Leslie L. Popplewell, Scott R. Solomon, Michael T. Tees, Yongzi Yu, Aiesha Zia, Stephen Lim, Avishek Pal, Pei Hsu, Frederick Locke

Blood (2024) 144 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2024-204207

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Strouse, Umar Farooq, Roni Shouval, Anusha Vallurupalli, Amy Moskop, Caron A. Jacobson, Frederick Locke, John H. Baird, Paolo Strati, Dilan A. Patel, Saurabh Dahiya, Michael T. Hemmer, Brad Du, Clare Spooner, Jenny J. Kim, Debbie L. Mirjah, Zhen-Huan Hu, Marcelo C. Pasquini, Yi Lin

Blood (2024) 144 (Supplement 1): 609.

https://doi.org/10.1182/blood-2024-207976

Published: 2024

Journal Articles

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Alaa Ali, Nausheen Ahmed, Soyoung Kim, Matthew Bye, Sayeef Mirza, Alex Gordon Sieg, Christopher Strouse, Kalyan Nadiminti, Priyanka A. Pophali, Rammurti T. Kamble, Lohith Gowda, Cameron J. Turtle, Christine L. Phillips, Marcelo C. Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop

Blood (2024) 144 (Supplement 1): 71.

https://doi.org/10.1182/blood-2024-200269

Published: 2024

Journal Articles

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Blood (2023) 142 (Supplement 1): 6912.

https://doi.org/10.1182/blood-2023-187462

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2023-189921

Published: 2023

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda

Blood (2022) 140 (Supplement 1): 4633–4635.

https://doi.org/10.1182/blood-2022-163750

Published: 2022

Journal Articles

Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups

Blood (2022) 140 (Supplement 1): 10386–10388.

https://doi.org/10.1182/blood-2022-165951

Published: 2022

Journal Articles

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Blood (2022) 140 (Supplement 1): 4661–4663.

https://doi.org/10.1182/blood-2022-169603

Published: 2022

Journal Articles

Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Blood (2022) 140 (Supplement 1): 10419–10421.

https://doi.org/10.1182/blood-2022-163336

Published: 2022

Journal Articles

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (21): 2138–2142.

https://doi.org/10.1182/blood.2021012392

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Overlap of post-CAR T HLH toxicity definitions and their prognostic significance in children and young adults with B-acute lymphoblastic leukemia

Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults

Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study

Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy

Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study

Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only